Publication | Open Access

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Lymphoid NeoplasiaAdvanced-stage Follicular LymphomaMedicineImmune Checkpoint InhibitorBiosimilar Ct-p10Non-inferiority Phase 3Cancer TreatmentImmunotherapyOncologyRadiation OncologyRadiologyHealth Sciences